Applied Biological Materials (abm) Company Profile
Background
Overview
Applied Biological Materials (abm) Inc., established in 2004, is a biotechnology company headquartered in Richmond, British Columbia, Canada. The company specializes in providing a comprehensive range of research reagents and custom services to the life sciences and drug development sectors. abm's mission is to assist scientists in achieving their research milestones by offering innovative products and services that streamline solutions and reduce costs. Their vision is to become a one-stop shop for high-quality, cost-effective research reagents, addressing the urgent needs of the drug discovery and biopharmaceutical markets.
Facilities
abm operates a state-of-the-art facility in Richmond, encompassing 27,000 square feet of wet lab and office space. This facility houses a cutting-edge R&D center and serves as the company's global logistics hub. In 2013, abm expanded its operations by establishing a 42,000 square foot branch in Zhenjiang, China, reflecting its commitment to embracing global market opportunities.
Key Strategic Focus
Core Objectives and Specializations
abm focuses on delivering a wide array of research reagents and custom services, including:
- Enzymes and PCR: Offering products for PCR, RT-PCR, and qPCR applications.
- Cell Lines: Providing stable and immortalized cell lines for various research needs.
- Antibodies: Supplying a diverse range of antibodies for research purposes.
- CRISPR: Offering CRISPR gene editing tools and services.
- Vectors and Viruses: Providing various viral expression systems, including adenovirus, lentivirus, and AAV.
- Custom Services: Delivering services such as custom recombinant adenovirus, lentivirus, cloning, gene synthesis, protein production, and sequencing.
These offerings are designed to support scientists in overcoming research challenges efficiently and cost-effectively.
Financials and Funding
Revenue and Employee Metrics
As of the latest available data, abm's estimated annual revenue is approximately $11.3 million, with a revenue per employee of $155,000. The company employs around 73 individuals, reflecting a 7% growth in employee count over the past year.
Funding History
Specific details regarding abm's funding history, including total funds raised and notable investors, are not publicly disclosed.
Pipeline Development
abm's product pipeline includes a diverse range of research reagents and services tailored to the life sciences and drug development industries. While specific timelines for product development and clinical trials are not publicly available, the company's continuous expansion of its product offerings indicates an ongoing commitment to innovation and meeting the evolving needs of the scientific community.
Technological Platform and Innovation
Proprietary Technologies and Scientific Methodologies
abm distinguishes itself through the development and commercialization of novel research tools and services. The company's product portfolio encompasses:
- PCR and qPCR Technologies: ISO 13456:2006 and 13485:2012 certified products for diagnostic use.
- CRISPR Gene Editing Tools: Providing advanced tools for precise gene editing applications.
- Custom Viral Vector Services: Offering tailored solutions for recombinant adenovirus and lentivirus production.
These innovations underscore abm's dedication to providing cutting-edge solutions that facilitate scientific discoveries.
Leadership Team
Key Executives
- Peter Li: Chief Executive Officer
- Heidi Chu: Director of Business Development
- Vivian Gao: Vice President of Corporate Development
- Lisa Young: Chief Financial Officer
These leaders bring a wealth of experience and expertise to abm, guiding the company's strategic direction and fostering its growth in the biotechnology sector.
Competitor Profile
Market Insights and Dynamics
The biotechnology industry is characterized by rapid innovation and a competitive landscape. abm operates within this dynamic environment, offering a broad spectrum of research reagents and services that cater to the diverse needs of the scientific community.
Competitor Analysis
Key competitors in the research reagents and services market include:
- Oxford Biomedical Research: Develops and markets assay kits, recombinant proteins, and antibodies for biomedical research and drug discovery.
- Polyplus-transfection: Specializes in nucleic acid delivery solutions for research, bioproduction, and therapeutics.
- Destina Genomics: Offers nucleic acid testing and molecular diagnostics assay solutions.
- Arista Biologicals: Manufactures and supplies rapid diagnostic reagents and equipment.
These companies represent significant competition in the biotechnology sector, each bringing unique products and services to the market.
Strategic Collaborations and Partnerships
In June 2023, abm entered into a license agreement with ERS Genomics Limited, granting abm access to ERS's CRISPR/Cas9 patent portfolio. This collaboration enhances abm's capabilities in gene editing technologies, enabling the development of new products and services in this rapidly evolving field.
Operational Insights
abm's strategic positioning in the biotechnology market is bolstered by its comprehensive product offerings and commitment to innovation. The company's ability to provide cost-effective, high-quality research reagents and services distinguishes it from competitors and aligns with the needs of the scientific community.
